Northern Trust Corp decreased its holdings in TESARO, Inc. (NASDAQ:TSRO) by 45.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 207,112 shares of the biopharmaceutical company’s stock after selling 172,387 shares during the quarter. Northern Trust Corp owned 0.38% of TESARO worth $28,967,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock worth $448,705,000 after buying an additional 103,759 shares during the last quarter. State Street Corp boosted its holdings in shares of TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock worth $152,617,000 after buying an additional 3,784 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of TESARO by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 703,774 shares of the biopharmaceutical company’s stock worth $98,430,000 after buying an additional 28,177 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its holdings in shares of TESARO by 39.4% in the second quarter. Pictet Asset Management Ltd. now owns 399,105 shares of the biopharmaceutical company’s stock worth $59,590,000 after buying an additional 112,869 shares during the last quarter.

TSRO has been the topic of a number of research reports. BidaskClub downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Friday, June 30th. Gabelli began coverage on shares of TESARO in a report on Friday, July 7th. They set a “buy” rating and a $175.00 price target on the stock. Janney Montgomery Scott reaffirmed a “neutral” rating on shares of TESARO in a report on Friday, July 14th. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the company a “buy” rating in a report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. TESARO currently has a consensus rating of “Hold” and an average price target of $170.19.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/northern-trust-corp-reduces-position-in-tesaro-inc-tsro/1642759.html.

In other news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares in the company, valued at approximately $823,439.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director James O. Armitage sold 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $1,171,300. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock worth $4,628,976 in the last quarter. Insiders own 40.50% of the company’s stock.

Shares of TESARO, Inc. (NASDAQ:TSRO) opened at 115.51 on Friday. The stock’s 50 day moving average is $121.22 and its 200 day moving average is $133.02. The company’s market cap is $6.26 billion. TESARO, Inc. has a 52-week low of $106.64 and a 52-week high of $192.94.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter last year, the business earned ($1.28) EPS. The company’s quarterly revenue was down 17.6% on a year-over-year basis. Equities analysts forecast that TESARO, Inc. will post ($8.72) EPS for the current year.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.